The United Kingdom and the United States have hammered out a significant commercial pact that will ensure zero tariffs on UK drug shipments going into the US market.
Agreement Details of the Deal
In exchange for the tariff guarantee, the UK has agreed to increase expenditure on pharmaceuticals through the National Health Service (NHS). This pledge guarantees that duties on these vital exports will be held at nothing for a period of the next three years.
This agreement comes after earlier threats to hike import taxes on branded pharmaceutical products, with potential rates floated reaching one hundred percent.
"This agreement with the United Kingdom reinforces the global environment for innovative medicines and introduces much-needed balance to American-British drug exports," a release noted.
Trade Importance
Drugs represent one of the UK's biggest exports to the United States, which is clearly the largest market for major companies like GSK and AstraZeneca.
Trade data indicate that in the one-year period to the end of September, the UK sold drugs worth £11.1bn to the US. This amount accounted for 17.4% of British export trade in that period.
"This deal secures work, boosts investment and paves the way for the UK to become a global hub for medical research," a government official remarked.
Key UK Commitments
The pact involves several notable changes from the UK:
- Price Threshold Increase: The UK will raise the cost ceiling at which it considers new treatments to be unaffordable by a quarter.
- Higher Drug Budget: There is a target to increase overall NHS spending on medicines from 0.3 percent of GDP to 0.6 percent over the coming ten years.
- Rebate Cap: The percentage drug companies must refund to the NHS to stay within budget will be limited at fifteen percent. In the past, rebates exceeded 20%.
Industry Background
The pact takes place against a long-running tension between the drug companies and the British authorities over drug pricing and regulatory access.
The disagreement were intensified by claims that American consumers were paying a premium for the same drugs than people in the UK and Europe.
Recently, several significant pharmaceutical investments in the UK have been halted or abandoned, while substantial investments have been directed toward projects in the United States.
A senior figure acknowledged that the NHS needed to spend more on treatments, noting that its expenditure on drugs had shrunk as a share of its total funding over the last ten years.
